{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:35:24Z","timestamp":1786977324195,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the high prevalence of brain metastases (BM) secondary to non\u2013small\u2010cell lung cancer (NSCLC) (NSCLC\/BM), patients' experiences (symptoms and impacts) are not fully understood. This study sought to understand the patient experience with NSCLC\/BM and identify a patient\u2010reported outcome (PRO) measure fit to capture the most important NSCLC\/BM symptoms and impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A targeted literature review was completed; the National Comprehensive Cancer Network (NCCN)\/Functional Assessment of Cancer Therapy\u2013Brain Symptom Index, 24\u2010item version (NFBrSI\u201024) was identified as a relevant measure that assessed the core symptoms and impacts associated with NSCLC\/BM. Qualitative interviews composed of concept elicitation and cognitive debriefing with oncologists (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) and adult patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) with NSCLC\/BM were conducted to confirm the content validity and evaluate the relevance and appropriateness of the NFBrSI\u201024 for this condition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NSCLC\/BM symptoms and impacts identified in the literature and reported by oncologists and patients were consistent and captured in the NFBrSI\u201024. Study participants reported significant burden associated with the symptoms (commonly fatigue, headache) and impacts of NSCLC\/BM. Participants indicated that the NFBrSI\u201024 captured their most salient experiences with NSCLC\/BM and that symptom improvement or a delay in progression, as measured by the NFBrSI\u201024, would be meaningful. During the cognitive debriefing, participants generally indicated that the NFBrSI\u201024 was comprehensive and easy to understand\/answer and that it assessed symptoms they considered most important to treat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that the NFBrSI\u201024 adequately captures an appropriate measure of NSCLC\/BM symptoms and impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.5975","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T10:29:26Z","timestamp":1686565766000},"page":"13637-13648","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Understanding the patient experience and treatment benefits in patients with non\u2013small\u2010cell lung cancer with brain metastasis"],"prefix":"10.1002","volume":"12","author":[{"given":"David","family":"Cella","sequence":"first","affiliation":[{"name":"Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Neuro\u2010Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ervin","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Vallow","sequence":"additional","affiliation":[{"name":"Novartis Services Inc.  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gilloteau","sequence":"additional","affiliation":[{"name":"Novartis Services Inc.  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"DeMuro","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Mordin","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chassot\u00a0Agostinho","sequence":"additional","affiliation":[{"name":"Novartis Services Inc.  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dine","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu199"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.05.06"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1481"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.007"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.3733"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.009"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2016.12.001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309105787"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.1739"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.2842"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-014-4044-2"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.09.009"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2035"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-016-0083-x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.08.006"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.858"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.04054.x"},{"key":"e_1_2_11_21_1","unstructured":"US Food and Drug Administration.Patient preference information\u2014voluntary submission review in premarket approval applications humanitarian device exemption applications and de novo requests and inclusion in decision summaries and device labeling.2016. FDA\u20102015\u2010D\u20101580. Accessed August 16 2021https:\/\/www.fda.gov\/media\/92593\/download"},{"key":"e_1_2_11_22_1","volume-title":"FDA Patient\u2010Focused Drug Development Guidance Series for Enhancing the Incorporation of the patient's Voice in Medical Product Development and Regulatory Decision Making","author":"US Food and Drug Administration","year":"2020"},{"key":"e_1_2_11_23_1","unstructured":"US Food and Drug Administration.Patient\u2010focused drug development: methods to identify what is important to patients guidance for industry food and drug administration staff and other stakeholders.2019. Accessed August 16 2021https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patient\u2010focused\u2010drug\u2010development\u2010methods\u2010identify\u2010what\u2010important\u2010patients\u2010guidance\u2010industry\u2010food\u2010and"},{"key":"e_1_2_11_24_1","unstructured":"US Food and Drug Administration.Patient\u2010reported outcome measures: use in medical product development to support labeling claims. October 17 2009.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patient\u2010reported\u2010outcome\u2010measures\u2010use\u2010medical\u2010product\u2010development\u2010support\u2010labeling\u2010claims.Accessed August 16 2021"},{"key":"e_1_2_11_25_1","unstructured":"US Food and Drug Administration.Methods to identify what is important to patients & select develop or modify fit\u2010for\u2010purpose clinical outcomes assessments.2018. Accessed August 16 2021https:\/\/www.fda.gov\/media\/116277\/download"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.006"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.11.006"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.103"},{"key":"e_1_2_11_29_1","first-page":"51","volume-title":"Qualitative Psychology: a Practical Guide to Research Methods","author":"Smith J","year":"2003"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020909529486"},{"key":"e_1_2_11_31_1","volume-title":"Designing and Conducting Mixed Methods Research","author":"Creswell J","year":"2018"},{"key":"e_1_2_11_32_1","unstructured":"US Food and Drug Administration.Patient\u2010focused drug development: collecting comprehensive and representative input.2020. Accessed August 16 2021https:\/\/www.fda.gov\/media\/139088\/download"},{"key":"e_1_2_11_33_1","volume-title":"Applied Thematic Analysis","author":"Guest G","year":"2011"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U"},{"key":"e_1_2_11_35_1","unstructured":"US Food and Drug Administration.Cancer clinical trial eligibility criteria: brain metastases guidance for industry.2020. Accessed August 16 2021https:\/\/www.fda.gov\/media\/121317\/download"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0097-2"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:06:57Z","timestamp":1699344417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/cam4.5975"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5975","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}